Bladder Cancer Trial, Recruiting NCT07495072 Sponsor: BLAD-HYA Group Condition: Bladder Cancer
Back to Bladder Cancer

Bladder Cancer Trial, Recruiting

NCT07495072
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 19 years or older
  • People who have been diagnosed with bladder cancer that has not grown into the muscle wall of the bladder, confirmed through a tissue sample examination
  • People whose doctors have identified them as suitable candidates for a treatment placed directly into the bladder called BCG therapy
  • People whose urine test showed no signs of infection before starting BCG therapy
  • People who are able to read and sign a consent form agreeing to take part in the trial

Who may not be able to join:

  • People who have had an allergic reaction or sensitivity to any ingredients in a product called Blad-Care
  • People for whom BCG therapy is considered medically unsuitable or unsafe
  • People who have a bladder that does not function properly due to nerve problems, or who have significant abnormalities in their urinary tract
  • People with severely reduced kidney function
  • People whose overall health or circumstances are considered by the trial doctor to make participation in the study inappropriate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chunwoo Lee, Kyung Hee University Hospital

Phone: +8229588897

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
BLAD-HYA Group
Registry
ClinicalTrials.gov
Start date
3 November 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Change from baseline in the combined Interstitial Cystitis Symptom Index (ICSI) and Interstitial Cystitis Problem Index (ICPI) score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov